{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:44:19Z","timestamp":1753875859416,"version":"3.41.2"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Motivation<\/jats:title>\n                  <jats:p>De novo drug development is a long and expensive process that poses significant challenges from the design to the preclinical testing, making the introduction into the market slow and difficult. This limitation paved the way to the development of drug repurposing, which consists in the re-usage of already approved drugs, developed for other therapeutic indications. Although several efforts have been carried out in the last decade in order to achieve clinically relevant drug repurposing predictions, the amount of repurposed drugs that have been employed in actual pharmacological therapies is still limited. On one hand, mechanistic approaches, including profile-based and network-based methods, exploit the wealth of data about drug sensitivity and perturbational profiles as well as disease transcriptomics profiles. On the other hand, chemocentric approaches, including structure-based methods, take into consideration the intrinsic structural properties of the drugs and their molecular targets. The poor integration between mechanistic and chemocentric approaches is one of the main limiting factors behind the poor translatability of drug repurposing predictions into the clinics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this work, we introduce DREAM, an R package aimed to integrate mechanistic and chemocentric approaches in a unified computational workflow. DREAM is devoted to the druggability evaluation of pathological conditions of interest, leveraging robust drug repurposing predictions. In addition, the user can derive optimized sets of drugs putatively suitable for combination therapy. In order to show the functionalities of the DREAM package, we report a case study on atopic dermatitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Availability and implementation<\/jats:title>\n                  <jats:p>DREAM is freely available at https:\/\/github.com\/fhaive\/dream. The docker image of DREAM is available at: https:\/\/hub.docker.com\/r\/fhaive\/dream.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bioinformatics\/btad442","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T19:07:36Z","timestamp":1689880056000},"source":"Crossref","is-referenced-by-count":0,"title":["DREAM: an R package for druggability evaluation of human complex diseases"],"prefix":"10.1093","volume":"39","author":[{"given":"Antonio","family":"Federico","sequence":"first","affiliation":[{"name":"Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University , Tampere 33100, Finland"},{"name":"Tampere Institute for Advanced Study, Tampere University , Tampere 33100, Finland"},{"name":"Division of Pharmaceutical Biosciences, Faculty of Pharmacy , University of Helsinki , Helsinki 00100, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Fratello","sequence":"additional","affiliation":[{"name":"Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University , Tampere 33100, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-0214","authenticated-orcid":false,"given":"Alisa","family":"Pavel","sequence":"additional","affiliation":[{"name":"Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University , Tampere 33100, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"M\u00f6bus","sequence":"additional","affiliation":[{"name":"Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University , Tampere 33100, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giusy","family":"del Giudice","sequence":"additional","affiliation":[{"name":"Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University , Tampere 33100, Finland"},{"name":"Division of Pharmaceutical Biosciences, Faculty of Pharmacy , University of Helsinki , Helsinki 00100, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Serra","sequence":"additional","affiliation":[{"name":"Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University , Tampere 33100, Finland"},{"name":"Tampere Institute for Advanced Study, Tampere University , Tampere 33100, Finland"},{"name":"Division of Pharmaceutical Biosciences, Faculty of Pharmacy , University of Helsinki , Helsinki 00100, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-9003","authenticated-orcid":false,"given":"Dario","family":"Greco","sequence":"additional","affiliation":[{"name":"Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University , Tampere 33100, Finland"},{"name":"Tampere Institute for Advanced Study, Tampere University , Tampere 33100, Finland"},{"name":"Division of Pharmaceutical Biosciences, Faculty of Pharmacy , University of Helsinki , Helsinki 00100, Finland"},{"name":"Institute of Biotechnology, University of Helsinki , Helsinki 00100, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"2023072802494653700_btad442-B1","doi-asserted-by":"crossref","first-page":"724277","DOI":"10.3389\/fimmu.2021.724277","article-title":"Drug repurposing for atopic dermatitis by integration of gene networking and genomic information","volume":"12","author":"Adikusuma","year":"2021","journal-title":"Front Immunol"},{"key":"2023072802494653700_btad442-B2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.25251\/skin.3.2.38","article-title":"Caffeine in the treatment of atopic dermatitis and psoriasis: a review","volume":"3","author":"Alashqar","year":"2019","journal-title":"J Skin"},{"key":"2023072802494653700_btad442-B3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjd.14537","article-title":"Vitamin D levels and atopic eczema in infancy and early childhood in Norway: a cohort study","volume":"175","author":"Berents","year":"2016","journal-title":"Br J Dermatol"},{"key":"2023072802494653700_btad442-B4","first-page":"9643543","article-title":"Successful treatment of severe atopic dermatitis with calcitriol and paricalcitol in an 8-year-old girl","volume":"2018","author":"Bothou","year":"2018","journal-title":"Case Rep Pediatr"},{"key":"2023072802494653700_btad442-B5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41597-020-00696-8","article-title":"Manually curated and harmonised transcriptomics datasets of psoriasis and atopic dermatitis patients","volume":"7","author":"Federico","year":"2020","journal-title":"Sci Data"},{"key":"2023072802494653700_btad442-B6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2217\/14622416.7.7.1025","article-title":"Toxicogenomics in drug discovery and development: mechanistic analysis of compound\/class-dependent effects using the DrugMatrix database","volume":"7","author":"Ganter","year":"2006","journal-title":"Pharmacogenomics"},{"key":"2023072802494653700_btad442-B7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/msb.2011.26","article-title":"PREDICT: a method for inferring novel drug indications with application to personalized medicine","volume":"7","author":"Gottlieb","year":"2011","journal-title":"Mol Syst Biol"},{"key":"2023072802494653700_btad442-B8","doi-asserted-by":"crossref","first-page":"i228","DOI":"10.1093\/bioinformatics\/btu278","article-title":"DrugComboRanker: drug combination discovery based on target network analysis","volume":"30","author":"Huang","year":"2014","journal-title":"Bioinformatics"},{"key":"2023072802494653700_btad442-B9","doi-asserted-by":"crossref","first-page":"D921","DOI":"10.1093\/nar\/gku955","article-title":"Open TG-GATEs: a large-scale toxicogenomics database","volume":"43","author":"Igarashi","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2023072802494653700_btad442-B10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archderm.1977.01640010109018","article-title":"Treatment of atopic dermatitis with topically applied caffeine\u2014a follow-up report","volume":"113","author":"Kaplan","year":"1977","journal-title":"Arch Dermatol"},{"key":"2023072802494653700_btad442-B11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/archderm.1978.01640130024007","article-title":"Topical use of caffeine with hydrocortisone in the treatment of atopic dermatitis","volume":"114","author":"Kaplan","year":"1978","journal-title":"Arch Dermatol"},{"key":"2023072802494653700_btad442-B12","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/bioinformatics\/bty063","article-title":"Inform: inference of network response modules","volume":"34","author":"Marwah","year":"2018","journal-title":"Bioinformatics"},{"key":"2023072802494653700_btad442-B13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","article-title":"Atopic dermatitis displays stable and dynamic skin transcriptome signatures","volume":"147","author":"M\u00f6bus","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023072802494653700_btad442-B14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2023072802494653700_btad442-B15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2023072802494653700_btad442-B16","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/ijd.14220","article-title":"Oral vitamin D3 5000 IU\/day as an adjuvant in the treatment of atopic dermatitis: a randomized control trial","volume":"57","author":"S\u00e1nchez-Armend\u00e1riz","year":"2018","journal-title":"Int J Dermatol"},{"key":"2023072802494653700_btad442-B17","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/archderm.1978.01640230087033","article-title":"Caffeine as an adjunct in the treatment of atopic dermatitis","volume":"114","author":"Siegel","year":"1978","journal-title":"Arch Dermatol"},{"key":"2023072802494653700_btad442-B18","doi-asserted-by":"crossref","first-page":"D431","DOI":"10.1093\/nar\/gkz1023","article-title":"LINCS Data Portal 2.0: next generation access point for perturbation-response signatures","volume":"48","author":"Stathias","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2023072802494653700_btad442-B19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"2023072802494653700_btad442-B20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jdcr.2018.09.012","article-title":"Topically applied low-dose calcitriol ameliorates atopic eyelid dermatitis","volume":"5","author":"Tukaj","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2023072802494653700_btad442-B21","doi-asserted-by":"crossref","first-page":"21116","DOI":"10.1038\/s41598-022-24980-2","article-title":"DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"2023072802494653700_btad442-B22","first-page":"1439","article-title":"Prospective investigation of 25(OH)D3 serum concentration following UVB narrow band phototherapy in patients with psoriasis and atopic dermatitis","volume":"36","author":"Weinhold","year":"2016","journal-title":"Anticancer Res"}],"container-title":["Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformatics\/advance-article-pdf\/doi\/10.1093\/bioinformatics\/btad442\/50918233\/btad442.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/39\/7\/btad442\/50978614\/btad442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/39\/7\/btad442\/50978614\/btad442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T02:50:23Z","timestamp":1690512623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article\/doi\/10.1093\/bioinformatics\/btad442\/7227071"}},"subtitle":[],"editor":[{"given":"Pier Luigi","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bioinformatics\/btad442","relation":{},"ISSN":["1367-4811"],"issn-type":[{"type":"electronic","value":"1367-4811"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,7,1]]},"article-number":"btad442"}}